US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Enzymatica recruits experienced marketing director

Enzymatica strengthens its growth strategy by recruiting Anna Söderlund as Senior Director of Marketing & Sales. With extensive experience in the life science industry as well as in sales and marketing, Anna brings valuable expertise to the company.– Enzymatica has an incredibly exciting product in ColdZyme, and I look forward to helping more consumers discover it. Products that can be marketed directly to the end user are both interesting and rewarding to work with.Read the full article at biostock.se : https://www.biostock.se/en/2025/01/enzymatica-

Interim report Q3/2024: Focus on developing existing and new markets

Third quarter January-September · Net sales · Net sales reached SEK 28.4 (35.1)reached SEK 12.6 million.(13.3) · The operating result totaled SEK -38.3 (million. -34.3) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.23 (-0.22).-6.4 (-8.7) · Cash flow from operating activities formillion. the period totaled SEK -40.0 (-37.7) · Earnings per million.share, basic anddiluted, were SEK-0.04 (-0.06). · Cash flow fromoperatingactivities totaled

Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (”Enzymatica” or ”Company”) today announces the outcome of the new share issue with preferential rights for existing shareholders that was resolved by the Board of Directors on July 18, 2024, and

BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica’s mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/final-study-

Enzymatica publishes supplementary prospectus

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (“Enzymatica” or “Company”) has issued a supplement (the “Supplementary Prospectus”) in addition to the EU growth prospectus that has been approved and registered by the Swedish Financial

Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

The study, which has now been completed, is an independent, investigator-initiated, randomised, double-blind placebo study led by Professor Glen Davison, Head of School of Sport and Exercise Sciences at the University of Kent in England. The secondary endpoints have now been reported as significant. All the results are official on the trial registry site: https://doi.org/10.1186/ISRCTN18133939.The study involved 164 endurance athletes who used either ColdZyme or placebo when experiencing upper respiratory tract infection symptoms. The difference between ColdZyme and placebo proved

Publication of prospectus regarding Enzymatica’s rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The prospectus (the “Prospectus”) for Enzymatica AB’s rights issue of around SEK 130 million (the “Rights issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).The

Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.

The University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial. The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England."The final analysis of the completed is still ongoing, but data for the primary endpoint, namely the duration of URTI infection are now final. The findings are really exciting as they show statistically significant reduction

Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Enzymatica AB (publ) (the “Company”) held an extraordinary general meeting on 6 August 2024. At the extraordinary general meeting, the following resolutions, amongst others, were made.Approval of the board of directors’ resolution on a rights issue of new shares The meeting resolved to approve the board of directors’ resolution from 18 July 2024, to increase the Company’s share capital by a maximum amount

Interim report Q2/2024: Enzymatica builds momentum for expansion

Second quarter January-June · Net sales · Net sales reached SEK 15.8 (21.8)reached SEK 6.4 million.(8.8) · The operating result totaled SEK -31.9 (million. -25.5) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.19 (-0.16).-13.5 (-11.2) · Cash flow from operating activities formillion. the period totaled SEK -26.3 (-21.7) · Earnings per million.share, basic anddiluted, were SEK-0.08 (-0.07). · Cash flow fromoperatingactivities totaledSEK

Enzymatica's Board of Directors updates the financial targets

The Board of Directors of Enzymatica AB (publ) has decided to update the company's financial goals. The background is that the company will likely develop the company's business model, so that in addition to being a producer of consumer products, Enzymatica will also become a supplier of enzyme formulations. The new business model is estimated to yield a higher EBIT margin, but lower net sales compared to the calculations that were the basis for the previous financial targets. In November 2021, Enzymatica's board decided that the company's financial goal would be a net turnover of at

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM") to be held on August 6, 2024 at 13:00 CET at Ideon Science Park, Scheelevägen 19 in Lund. Notification etc. Those who wish to participate in the annual general meeting must:   i. be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of July 29, 2024; andii. give notice of intent to participate no later than July 31, 2024.

Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The board of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue of approximately SEK 130 million with preferential rights for existing shareholders (the “Rights issue”). The Rights issue is

Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days

University of Kent has earlier this afternoon published interim results from the ongoing double-blind, placebo-controlled, randomized on the effects of ColdZyme and the product’s effect on treating the symptoms and duration of Upper Respiratory Tract Infections (URTI). Interim results have showed that Enzymatica's ColdZyme® oral spray reduces the amount of rhinovirus and reduces the number of sick days by approximately five days, with number of sick days being the primary endpoint of the study. The study is an independent, investigator-initiated in vivo study led by Glen Davison, professor

Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Enzymatica AB (publ) held its annual general meeting on May 7, 2024. At the annual general meeting, the following resolutions were made. Income statements and balance sheets The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet. Disposition of the company’s profit or loss The general meeting resolved, in

BioStock: MDR certification was Enzymatica’s highlight in Q1

Enzymatica has recently published its Q1 report, where the MDR certification for ColdZyme stands out as the key milestone during the quarter.– The MDR certification was a labor-intensive and costly process, but now that ColdZyme has been certified as one of the first cold products in Europe, it opens up great commercial opportunities.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/mdr-certification-was-enzymaticas-highlight-in-q1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Interim report Q1/2024: MDR certification opens up great commercial opportunities

First quarter · Net sales reached SEK 9.4 (13.0) million. · The operating result totaled SEK -18.4 (-14.4) million. · Earnings per share, basic and diluted, were SEK -0.11 (-0.09). · Cash flow from operating activities totaled SEK -7.3 (-12.2) million.   CEO Comment “Sales for the first quarter were lower than the same period last year, which in its entirety is due to the low partner sales. In the Swedish market, sales were up by 21% compared to the same quarter last year, and our market share continues to increase. During the quarter, ColdZyme was MDR certified as

Notice of Annual General Meeting 2024 in Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The annual general meeting of Enzymatica AB (publ), reg. no. 556719-9244, will be held on 7 May 2024 at 14:30 CET, Elite Hotel Ideon, Scheelevägen 27 in Lund.Notification etc. Those who wish to participate in the annual general meeting must: (i)       be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 26 April 2024;

BioStock: Enzymatica comments on MDR certification for ColdZyme

Enzymatica has received CE certification for ColdZyme under the EU’s new Medical Device Regulation. According to the company, this is an important milestone that validates their scientific and regulatory foundation. Additionally, the certification provides an opportunity to expand both the intended use and product claims for ColdZyme. BioStock interviewed Ann-Christine Provoost, Director Regulatory Affairs, to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/enzymatica-comments-on-mdr-certification-for-coldzyme/ This

Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors for Enzymatica (”Enzymatica” or ”Company”) today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 16 February 2024 (the “Rights issue”

ColdZyme® certified under the new EU medical device regulation (MDR)

Enzymatica’s mouth spray ColdZyme® has received CE-certification under the new and more demanding European Union medical device regulation (MDR). This important milestone validates the company’s scientific data and extends product claims throughout the EU. The certification is a key pillar for expansion in several markets and is expected to have long-term positive effects on Enzymatica’s growth. Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation. MDR replaces

BioStock: Enzymatica’s partners await MDR certification and study results

Enzymatica has published its year-end report, revealing an operating result of SEK -48.1 million and net sales of SEK 50.9 million for the full year. While sales increased in Sweden, the order intake from partners in other markets has been below expectations. To reverse this trend, MDR certification and study result will be crucial factors, according to CEO Claus Egstrand.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/enzymaticas-partners-await-mdr-certification-and-study-results/ This is a press release from BioStock -

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe